ASX Announcement: Atomo and NG Biotech expand COVID-19 partnership:
Atomo secures exclusive rights for Australia, New Zealand and South East Asia¹ SYDNEY Australia, Thursday, 4 June 2020 – Atomo Diagnostics Limi...
04 June, 2020
Atomo’s innovative rapid diagnostic test (RDT) platforms simplify procedures, mitigate common user errors, and enhance test performance. Their unmatched usability has won the respect of frontline healthcare providers worldwide, and has made Atomo the OEM partner of choice for diagnostic companies wanting to enhance their RDT product offerings.
Unmatched Usability
User-centred design for professional use & self-test applications.
Proven Performance
Award-winning device platforms that are proven to mitigate user errors.
Efficient Development
Validated processes to accelerate custom device development.
Integrated RDT platforms
Award-winning AtomoRapid™ RDT platforms remove the need for multiple test components by integrating features into a single device. With assorted functionality, Atomo platforms greatly simplify test procedures.
Self-testing made simpler
With a built-in safety lancet, unique blood collection feature, single action blood and buffer delivery system, and interlocked user steps, the AtomoRapid™ Elion self-test platform provides unprecedented usability and performance.
Custom device development
Devices are customisable to suit your requirements and modified to match the specifics of your test strip. From manufacturing process validation to post launch marketing, benefit from Atomo’s dedicated support every step of the way.
Atomo HIV Self Test
The Atomo HIV Self Test is now available in Australia directly from Atomo Diagnostics, and is the first and only HIV self-test to have been approved by the Australian Therapeutic Goods Administration (TGA).
Partner with Atomo for an efficient, low-risk pathway from product development to commercialisation of your best-in-class rapid diagnostic test.
Get in touch >
Atomo News
-
-
MEDIA RELEASE: Atomo Diagnostics to list on ASX after successful IPO and virtual bell ringing ceremony
SYDNEY Australia 16 April 2020– Following an oversubscribed initial public offering and the first ASX virtual bell ringing listing, trading of shares ...
16 April, 2020
Following @Qantas CEO Alan Joyce’s comments that a COVID-19 vaccine will be necessary for international travellers here: https://bit.ly/2J5ZCjA, we believe rapid COVID-19 antibody testing will have a key role in efficiently verifying vaccine delivery + a robust antibody response
We agree with Dr Ian Norton from @global_respond that rapid COVID-19 point of care testing could hold the key to preventing outbreaks from Australian hotel quarantine sites.
Read more here: https://bit.ly/2UEyCKH
Coverage on TGA approval of the AtomoRapid HIV 1&2 rapid diagnostic test (RDT) for professional use in @BiotechDispatch.
Read here: https://bit.ly/38BTnPt
If a vaccine is ineffective, both antigen and antibody testing will still be needed.
Read more here: https://bit.ly/3eV78tN
We agree with Sonic Healthcare CEO, Dr Colin Goldschmidt that COVID-19 testing will LIKELY be needed well into the future despite any vaccine being rolled out.